Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3992304 | 1.00 | DPP4 (0.51) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL25663565 | 1.00 | DPP4 (0.51) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL3985105 | 1.00 | DPP4 (0.51) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL19510002 | 0.86 | DPP4 (0.47) | DPP4DPP7DPP8 | |
| SCHEMBL18752140 | 0.86 | DPP4 (0.47) | DPP4DPP7DPP8 | |
| SCHEMBL28261299 | 0.86 | DPP4 (0.47) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL743991 | 0.85 | DPP4 (0.53) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL571909 | 0.85 | DPP4 (0.53) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL29619671 | 0.85 | DPP4 (0.53) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL743042 | 0.85 | DPP4 (0.53) | DPP4DPP7DPP8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116891838-B | Alkene reductase mutant, composition, biological material and application thereof | 瑞博(苏州)制药有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-116891838-A | Alkene reductase mutant, composition, biological material and application thereof | 瑞博(苏州)制药有限公司 | 2023-10-17 | — | — | CN | disclosed |
| EP-3156391-B1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-10189760-B2 | Method for preparing sitagliptin intermediate via asymmetrical reduction method | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2019-01-29 | — | — | US | disclosed |
| US-9873651-B2 | — | — | 2018-01-23 | — | — | US | disclosed |
| US-9873651-B2 | — | — | 2018-01-23 | — | — | US | disclosed |
| US-20170305822-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170305822-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-10-26 | — | — | US | disclosed |
| EP-2308829-B1 | A PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-06-14 | — | — | EP | disclosed |
| EP-3156391-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2017-04-19 | — | — | EP | disclosed |
| US-8580997-B2 | Process for preparing R-beta-amino phenylbutyric acid derivatives | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2013-11-12 | — | — | US | disclosed |
| WO-2013114173-A1 | A NOVEL PROCESS FOR THE PREPARATION OF SITAGLIPTIN | SMILAX LABORATORIES LIMITED (IN) | 2013-08-08 | — | — | WO | disclosed |
| US-20110130587-A1 | PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2011-06-02 | — | — | US | disclosed |
| EP-2308829-A1 | A PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2011-04-13 | — | — | EP | disclosed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
| WO-2009064476-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192326-A1 | Preparation of sitagliptin intermediate | DPP4, DPP7, DPP3 | DPP4 1/4885DPP9 4/4885DPP7 2/4885 |
| US-20170305822-A1 | METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD | DPP4, DPP7, SI | DPP4 1/4885DPP9 4/4885DPP7 2/4885 |
| US-20110130587-A1 | PROCESS FOR PREPARING R-BETA-AMINO PHENYLBUTYRIC ACID DERIVATIVES | ALAD, DAO, DDO | DPP4 20/4885DPP9 184/4885DPP7 170/4885 |
| US-10189760-B2 | Method for preparing sitagliptin intermediate via asymmetrical reduction method | DPP4, DPP7, SI | DPP4 1/4885DPP9 4/4885DPP7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.